Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts
Progress on US sales will be key for further Torrent Pharma's stock gains
In the past three months, Natco Pharma has outperformed the market by gaining 8 per cent, as compared to 8 per cent decline in the S&P BSE Sensex.
Pharma shares are likely to be in limelight as NPPA may allow up to 10 per cent hike on scheduled drugs in the month of April.
Infinity Holdings Group made an open offer to buy 26 per cent stake in the company at a price of Rs 235 per share
Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic
Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday
Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.
In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.
The company believes that this will not impact the existing business from this facility.
The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.
Pharma shares may be in focus as India's apex health research organization ICMR has raised concerns around the safety for use of the oral antiviral drug Molnupiravir
Reliance Jio plans its biggest ever rupee bond sale, while Bharti Airtel shelves its plans to de-merge its core telecom business
Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI
Textiles shares shall be in limelight as the government has released the operational guidelines for the production-linked incentive (PLI) scheme
The board of directors of the company is scheduled to consider a proposal for buy-back of equity shares on Tuesday, December 28.
The purpose of entering into the agreement is expansion of product portfolio to offer biotherapeutic options to the patients in cardio-metabolic segment, Eris said in statement
Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder
Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing
FMCG stocks are likely to be in focus on the back of price hike announced, while airline shares too may be on investor's radar following the fresh world-wide Coivd-19 scare